Stockscreener 앱 받기
11.66
1.93%
-0.23
시간 외 거래:
11.66
전일 마감가:
$11.89
열려 있는:
$11.89
하루 거래량:
1.53M
Relative Volume:
1.03
시가총액:
$669.71M
수익:
-
순이익/손실:
$-52.79M
주가수익비율:
-14.97
EPS:
-0.7789
순현금흐름:
$-53.49M
1주 성능:
-17.01%
1개월 성능:
-34.64%
6개월 성능:
+67.05%
1년 성능:
+455.24%
1일 변동 폭
$11.53
$11.92
1주일 범위
$11.38
$14.39
52주 변동 폭
$1.54
$18.33
Climb Bio Inc Stock (CLYM) Company Profile
명칭
Climb Bio Inc
전화
1-866-857-2596
주소
20 WILLIAM STREET, WELLESLEY HILLS
Compare CLYM vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
11.66 | 669.71M | 0 | -52.79M | -53.49M | -0.7789 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-15 | 개시 | Mizuho | Outperform |
| 2026-03-24 | 개시 | B. Riley Securities | Buy |
| 2026-03-18 | 개시 | Truist | Buy |
| 2026-03-11 | 개시 | Raymond James | Strong Buy |
| 2026-03-05 | 개시 | Wedbush | Outperform |
| 2026-02-13 | 개시 | Piper Sandler | Overweight |
| 2025-10-16 | 개시 | William Blair | Outperform |
| 2025-10-13 | 개시 | H.C. Wainwright | Buy |
| 2025-08-15 | 개시 | Robert W. Baird | Outperform |
| 2025-06-06 | 개시 | Oppenheimer | Outperform |
| 2025-05-22 | 개시 | BTIG Research | Buy |
| 2024-12-02 | 개시 | Leerink Partners | Outperform |
모두보기
Climb Bio Inc 주식(CLYM)의 최신 뉴스
Raymond James adds Climb Bio stock to favorites list on drug potential - Investing.com Canada
Climb Bio, Inc.(NasdaqGM: CLYM) added to S&P Biotechnology Select Industry Index - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to S&P Global BMI Index - marketscreener.com
Director Stephen Thomas Sells 100,000 Shares of Climb Bio Inc (CLYM) - GuruFocus
Climb Bio (CLYM) director sells 100K shares in preset plan - Stock Titan
CLYM: CLYM116 and budoprutug advance with best-in-class data, Q12-week dosing, and pivotal trials ahead - TradingView
CLYM: CLYM116 and budoprutug advance with best-in-class profiles and key data readouts expected soon - TradingView
Climb Bio (NASDAQ: CLYM) director files to sell insider stake - Stock Titan
CLYM Stock Price, Quote & Chart - ChartMill
Climb Bio presents initial Phase 1 data for CLYM116 - Traders Union
Climb Bio at Wells Fargo conference: two antibody bets draw focus - Investing.com Nigeria
H.C. Wainwright raises Climb Bio stock price target on drug data By Investing.com - Investing.com Australia
H.C. Wainwright raises Climb Bio stock price target on drug data - Investing.com Australia
Oppenheimer Adjusts Price Target on Climb Bio to $25 From $18, Maintains Outperform Rating - Moomoo
Oppenheimer raises Climb Bio stock price target on IgAN data By Investing.com - Investing.com Canada
Oppenheimer raises Climb Bio stock price target on IgAN data - Investing.com
H.C. Wainwright Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $30 - Moomoo
Truist Financial Maintains Climb Bio(CLYM.US) With Buy Rating - Moomoo
A Quick Look at Today's Ratings for Climb Bio(CLYM.US), With a Forecast Between $25 to $40 - Moomoo
symbol__ Stock Quote Price and Forecast - cnn.com
Analysts Are Bullish on Top Healthcare Stocks: Climb Bio (CLYM), Phreesia (PHR) - The Globe and Mail
Baird raises Climb Bio stock price target to $25 on trial data - Investing.com Canada
BTIG raises Climb Bio stock price target to $32 on phase 1 data - Investing.com Australia
Baird raises Climb Bio stock price target to $25 on trial data By Investing.com - Investing.com South Africa
BTIG raises Climb Bio stock price target to $32 on phase 1 data By Investing.com - Investing.com South Africa
Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug - Yahoo Finance
Climb Bio Announces Positive Phase 1 Trial Outcomes for CLYM116 Targeting IgA Nephropathy - Kalkine Media
Baird Initiates Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $25 - Moomoo
Climb Bio’s Kidney Disease Therapy Gets Support for Extended Dosing Schedule - Benzinga
Climb Bio rises on trial data for kidney drug (CLYM:NASDAQ) - Seeking Alpha
CLYM: CLYM116 shows robust, durable APRIL and IgA suppression with a favorable safety profile in phase I - TradingView
Climb Bio Shares Rise 17% After Phase 1 CLYM116 Trial Data - Yahoo Finance
Why is Climb Bio stock sliding today? By Investing.com - Investing.com Canada
Climb Bio Reports Encouraging Initial Phase 1 CLYM116 Data - TipRanks
Climb Bio stock surges 17% on positive drug trial results - Investing.com
Climb Bio stock surges 17% on positive drug trial results By Investing.com - Investing.com India
Climb Bio reports phase 1 data for IgA nephropathy drug By Investing.com - Investing.com Nigeria
Climb Bio reports phase 1 data for IgA nephropathy drug - investing.com
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating - globenewswire.com
Climb Bio to Present at Upcoming Investor Conferences - markets.businessinsider.com
Climb Bio Stock Up In Pre-Market Ahead Of CLYM116 Data Tomorrow - RTTNews
Climb Bio Inc. (CLYM) Holds Gains: Stock Trades at $13.9 as $14.6 Resistance Caps UpsideLeveraged ETF Flow - dars.gov.et
CLYM Q2 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesPeak Earnings Alert - dars.gov.et
CLYM Q2 2026 Earnings: Narrowed Loss Per Share Beats Estimates, Stock Still Slips 3.25%Earnings Forecast Report - careplusvn.com
Should Climb Bio’s IgA Nephropathy Phase 2 Partnership Shift How CLYM Investors View Its Pipeline Strategy? - Sahm
Climb Bio Inc (CLYM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):